Puma Biotechnology Q4 Earnings Call Highlights

Core Insights - Puma Biotechnology reported a total revenue of $75.5 million for Q4 2025, driven by NERLYNX product revenue of $59.9 million and a significant increase in royalty revenue to $15.6 million [5][4][7] Financial Performance - Q4 2025 product revenue net, consisting entirely of NERLYNX sales, totaled $59.9 million, an increase from $51.9 million in Q3 2025 and $54.4 million in Q4 2024 [4] - GAAP net income for Q4 2025 was $13.4 million, or $0.20 per basic share, compared to $8.8 million in Q3 2025 [19] - Non-GAAP net income for Q4 2025 was $15.1 million, or $0.30 per basic share, excluding stock-based compensation [19] - Gross revenue from NERLYNX sales was $82.9 million in Q4 2025, up from $70.0 million in Q3 2025 [20] Inventory and Sales Dynamics - Management noted an inventory build of approximately $5.7 million at specialty pharmacies, impacting Q4 product revenue [3][7] - New prescriptions decreased by about 11.4% compared to Q3 2025, while total prescriptions increased by 1.4% [2] Clinical Development - The ALISCA-Breast1 trial for alisertib reached enrollment ahead of schedule with 164 patients, and interim data is expected in Q2 2026 [6][15] - The ALISCA-Lung1 trial is examining alisertib monotherapy, with preliminary data suggesting better activity in patients with relevant biomarkers [16] Guidance and Future Outlook - For 2026, Puma expects net NERLYNX product revenue of $194–$198 million and royalties of $20–$23 million, with a projected net income of $10–$13 million [7][22] - Q1 2026 guidance includes net NERLYNX product revenue of $36 million to $39 million and a projected net loss of $8 million to $10 million [23] Marketing and Sales Strategy - The sales team is focused on expanding healthcare provider reach, with Q4 2025 call activity increasing by 23% year over year [8] - NERLYNX demand increased by about 7% quarter over quarter and 7% year over year, with specialty distributor demand growing by 17% sequentially [9][10] Cost and Cash Management - Cost of sales in Q4 2025 was $23.2 million, including $2.4 million of amortization related to the neratinib license [21] - Puma generated approximately $3.1 million of cash in Q4 2025, with outstanding principal debt declining to approximately $22 million [25]